The report will be delivered in 2-3 business days.

Ovarian Cancer Drugs Global Market Report 2019

Starting Price : $ 4000.00 | Pages : 200 | Published : December 2019 | SKU CODE : 7221 | Format :


The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.

The global ovarian cancer drugs market was valued at about $1.3 billion in 2018 and is expected to grow to $1.99 billion at a CAGR of 11.2% through 2022.

North America was the largest region in the ovarian cancer drugs market in 2018, followed by Europe. This region is expected to remain the largest during the next five years.

The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. In 2018, according to the World Cancer Research Fund International (WCRF), there were nearly 300,000 new ovarian cancer cases recorded globally. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition 2018, an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to a report on cancer facts and figures 2018, the estimated number of new cancer cases and deaths in the USA, in 2018 were 1,735,350 and 609,640 respectively. Furthermore, in 2018, there were approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

Increasing use of biologics and targeted therapies are restraining the Ovarian Cancer drugs market growth. Targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroying normal cells. For example, Bevacizumab is a targeted therapy biologics drugs used to treat Ovarian Cancer. A targeted therapy drug, Zejula was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in drug pipeline. FDA has also approved Genentech’s biologics license for ovarian cancer drugs highlighting the fact many new companies are entering into the biologics ovarian drug cancer market. Hence, the growing popularity of alternatives such as biologics and targeted therapies may hinder the growth of ovarian cancer drugs market.

Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consists of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions. The pharmaceutical companies in the ovarian cancer drugs market are investing on the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche's blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA in 2018, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advance stage (III or IV) ovarian cancer.

The Ovarian cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for ovarian cancer drugs market in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of ovarian cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in ovarian cancer drugs industry are required to abide to the regulations under FDA.

In January 2019, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, acquired Tesaro for $5.1 billion. This acquisition would enable GSK to expand its product portfolio with Tesaro’s Zejula, PARP inhibitor and others, improve significant opportunities in strengthening GSK’s pharmaceutical business by accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer. Tesaro was founded in 2010 and headquartered in Waltham, Massachusetts, USA.

Major players in the market are AstraZeneca, Roche, Tesaro, Clovis Oncology, Boehringer Ingelheim

    1. Executive Summary

    2. Ovarian Cancer Drugs Market Characteristics

    3. Ovarian Cancer Drugs Market Size And Growth

    3.1. Global Ovarian Cancer Drugs Historic Market, 2014 - 2018, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Ovarian Cancer Drugs Forecast Market, 2018 - 2022F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Ovarian Cancer Drugs Market Segmentation

    4.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Epithelial Ovarian Cancer

    Ovarian Low Malignant Potential Tumor

    Germ Cell Tumor

    Sex Cord-Stromal Tumor

    4.2. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Hospital Pharmacies

    Drug Stores

    Others

    4.3. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Alkylating Agents

    Mitotic Inhibitors

    Antirheumatics

    Antipsoriatics

    VEGF/VEGFR inhibitors

    PARP inhibitors

    Antineoplastics

    Others

    5. Ovarian Cancer Drugs Market Regional And Country Analysis

    5.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    5.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Ovarian Cancer Drugs Market  

    6.1. Asia-Pacific Ovarian Cancer Drugs Market Overview  

    6.2. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6.4. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    7. China Ovarian Cancer Drugs Market  

    7.1. China Ovarian Cancer Drugs Market Overview  

    7.2. China Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    7.3. China Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    7.4. China Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    8. India Ovarian Cancer Drugs Market  

    8.1. India Ovarian Cancer Drugs Market Overview  

    8.2. India Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    8.3. India Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    8.4. India Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9. Japan Ovarian Cancer Drugs Market  

    9.1. Japan Ovarian Cancer Drugs Market Overview  

    9.2. Japan Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9.3. Japan Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9.4. Japan Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10. Australia Ovarian Cancer Drugs Market  

    10.1. Australia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10.2. Australia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10.3. Australia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11. Indonesia Ovarian Cancer Drugs Market  

    11.1. Indonesia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11.2. Indonesia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11.3. Indonesia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12. South Korea Ovarian Cancer Drugs Market  

    12.1. South Korea Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12.2. South Korea Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12.3. South Korea Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13. Western Europe Ovarian Cancer Drugs Market  

    13.1. Western Europe Ovarian Cancer Drugs Market Overview

    13.2. Western Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13.3. Western Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13.4. Western Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14. UK Ovarian Cancer Drugs Market  

    14.1. UK Ovarian Cancer Drugs Market Overview

    14.2. UK Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14.3. UK Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14.4. UK Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15. Germany Ovarian Cancer Drugs Market  

    15.1. Germany Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15.2. Germany Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15.3. Germany Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16. France Ovarian Cancer Drugs Market  

    16.5. France Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16.6. France Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16.7. France Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17. Eastern Europe Ovarian Cancer Drugs Market  

    17.1. Eastern Europe Ovarian Cancer Drugs Market Overview

    17.2. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17.4. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18. Russia Ovarian Cancer Drugs Market  

    18.1. Russia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18.2. Russia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18.3. Russia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19. North America Ovarian Cancer Drugs Market  

    19.1. North America Ovarian Cancer Drugs Market Overview

    19.2. North America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19.3. North America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19.4. North America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20. USA Ovarian Cancer Drugs Market  

    20.1. USA Ovarian Cancer Drugs Market Overview

    20.2. USA Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20.3. USA Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20.4. USA Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21. South America Ovarian Cancer Drugs Market  

    21.1. South America Ovarian Cancer Drugs Market Overview

    21.2. South America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21.3. South America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21.4. South America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22. Brazil Ovarian Cancer Drugs Market  

    22.1. Brazil Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22.2. Brazil Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22.3. Brazil Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23. Middle East Ovarian Cancer Drugs Market  

    23.1. Middle East Ovarian Cancer Drugs Market Overview

    23.2. Middle East Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23.3. Middle East Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23.4. Middle East Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24. Africa Ovarian Cancer Drugs Market  

    24.1. Africa Ovarian Cancer Drugs Market Overview

    24.2. Africa Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24.3. Africa Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24.4. Africa Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    25. Ovarian Cancer Drugs Market Competitive Landscape And Company Profiles

    25.1. Ovarian Cancer Drugs Market Competitive Landscape

    25.2. Ovarian Cancer Drugs Market Company Profiles

    25.2.1. AstraZeneca

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Roche

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Tesaro

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Clovis Oncology

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Boehringer Ingelheim

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market

    27. Ovarian Cancer Drugs Market Trends And Strategies

    28. Product Pipeline Analysis

    29. Ovarian Cancer Drugs Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Table 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 65: AstraZeneca Financial Performance
  • Table 66: Roche Financial Performance
  • Table 67: Tesaro Financial Performance
  • Table 68: Clovis Oncology Financial Performance
  • Table 69: Boehringer Ingelheim Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Figure 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Figure 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 65: AstraZeneca Financial Performance
  • Figure 66: Roche Financial Performance
  • Figure 67: Tesaro Financial Performance
  • Figure 68: Clovis Oncology Financial Performance
  • Figure 69: Boehringer Ingelheim Financial Performance
Research And Development Initiatives Taken In The Anti-Infective Drugs Market
Research Initiatives And Funding And Demand For New Medicines For Drug-Resistant Infections In The Anti-Infective Drugs Industry
Global Biologics Market, Opportunities And Strategies Market | Characteristics, Forecast Size, Trends
Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions and By Key Players - Global Forecast To 2021
View Report
Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022
View Report
Cardiovascular Drugs Global Market Report 2019
View Report
Dermatology Drugs Global Market Report 2019
View Report
Gastrointestinal Drugs Global Market Report 2019
View Report
Hematology Drugs Global Market Report 2019
View Report
Metabolic Disorders Drugs Global Market Report 2019
View Report
Musculoskeletal Disorders Drugs Global Market Report 2019
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)